ReviewMedicina (Kaunas, Lithuania)2022
Treatment of Prolactinoma.
Review in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 46 citations in OpenAlex.
- [Impulse control disorder: patients with pituitary adenomas and dopaminergic agonists].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- Recurrent nasal bleed as initial presenting complaint: a rare complication of giant prolactinoma in a 39-year-old.Annals of medicine and surgery (2012) · 2026Article
- Review
- Secondary Loss of Response to Dopamine Receptor Agonists in the Treatment of Macroprolactinoma.Cureus · 2025Article
- Wogonin inhibits the proliferation of prolactinoma through the PI3K/AKT signaling pathway.Frontiers in pharmacology · 2025Article
- Hormonally Active Pituitary Adenomas and Pregnancy: A Systematic Review.Medical journal of the Islamic Republic of Iran · 2025Review
- Long-term survival in a patient with metastatic prolactinoma: a 12-year follow-up.Proceedings (Baylor University. Medical Center) · 2025Article
- Optical coherence tomography and electroretinography in pituitary macroadenomas: a 12-month analysis by age and tumor type.Frontiers in endocrinology · 2025Observational
- Genetic and Functional Changes in Mitochondria in the Pituitary Adenoma: The Pathogenesis and Its Therapy.Antioxidants (Basel, Switzerland) · 2024Review
- Advancements in Molecular Diagnosis and Pharmacotherapeutic Strategies for Invasive Pituitary Adenomas.Immunity, inflammation and disease · 2024Review
- Identification of Prolactinoma in Pituitary Neuroendocrine Tumors Using Radiomics Analysis Based on Multiparameter MRI.Journal of imaging informatics in medicine · 2024Article
- Clinical parameters and postoperative outcomes of pituitary adenomas in children: Analysis according to size of adenomas and adopted surgical procedures.Molecular and clinical oncology · 2024Article
- Gender Differences in Patients with Prolactinoma: Single-center Ukrainian Experience.Reviews on recent clinical trials · 2024Article
- Prognostic factors for surgical treatment of prolactin-secreting pituitary adenomas.Frontiers in surgery · 2024Article
- Oxidative stress in pituitary neuroendocrine tumors: Affecting the tumor microenvironment and becoming a new target for pituitary neuroendocrine tumor therapy.CNS neuroscience & therapeutics · 2023Review
- Challenges of Pituitary Apoplexy in Pregnancy.Journal of clinical medicine · 2023Review
- Pituitary Tumorigenesis-Implications for Management.Medicina (Kaunas, Lithuania) · 2023Review
- Approach of Acromegaly during Pregnancy.Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prolactinomas are the commonest form of pituitary neuroendocrine tumor (PitNET), representing approximately half of such tumors. Dopamine agonists (DAs) have traditionally been the primary treatment for the majority of prolactinomas, with surgery considered the second line. The aim of this review is to examine the historical and modern management of prolactinomas, including medical therapy with DAs, transsphenoidal surgery, and multimodality therapy for the treatment of aggressive prolactinomas and metastatic PitNETs, with an emphasis on the efficacy, safety, and future directions of current therapeutic modalities. DAs have been the mainstay of prolactinoma management since the 1970s, initially with bromocriptine and more recently with cabergoline. Cabergoline normalizes prolactin in up to 85% of patients and causes tumor shrinkage in up to 80%. Primary surgical resection of microprolactinomas and enclosed macroprolactinomas performed by experienced pituitary neurosurgeons have similar remission rates to cabergoline. Aggressive prolactinomas and metastatic PitNETS should receive multimodality therapy including high dose cabergoline, surgery, radiation therapy (preferably using stereotactic radiosurgery where suitable), and temozolomide. DAs remain a reliable mode of therapy for most prolactinomas but results from transsphenoidal surgery in expert hands have improved considerably over the last one to two decades. Surgery should be strongly considered as primary therapy, particularly in the setting of microprolactinomas, non-invasive macroprolactinomas, or prior to attempting pregnancy, and has an important role in the management of DA resistant and aggressive prolactinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.